TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04940052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib will be administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib will be administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trametinib placebo
Description: Trametinib will be administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dabrafenib placebo
Description: Dabrafenib placebo will be administered orally twice daily
Study: NCT05732441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huange capsule
Description: Huange Capsule was orally administered (Zhejiang Kangenbe Pharmaceutical Co., Ltd., specification: 0.4g×60 tablets/bottle, GuoYaoZhunZi Z20110006). Administration method: 1.6g each time, three times a day, 40min after breakfast, lunch and dinner. The treatment course was four weeks.
Study: NCT04871204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Injection
Description: 10 mg Sandostatin LAR intramuscular injection
Study: NCT05682235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise AND pain neurophysiology education
Description: A program of therapeutic exercise and education in the neurophysiology of pain will be applied to the participants of the experimental group and talks on healthy habits to the placebo group participants.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Talk about healthy habits
Study: NCT05559801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mesenchymal stromal cells (MSCs)
Description: Mesenchymal stromal cells (MSCs) are cells of non-hematopoietic stromal origin that reside in bone marrow and a variety of tissues. MSCs will be prepared in a GMP Cell Production facility and administered to children age 3-10 years (at time of enrollment) with Osteogenesis Imperfecta Type III.
Study: NCT06297291

Intervention type: DEVICE
Intervention: Paradise Ultrasound Renal Denervation Treatment
Description: The Paradise Ultrasound Renal Denervation System (Paradise Ultrasound RDN) is an FDA-approved catheter-based system to treat hypertension by ablating the nerves around the renal arteries, disrupting the overactive sympathetic nerves that can cause high blood pressure. The Paradise procedure uses ultrasound energy to calm the nerves near the kidneys to help lower blood pressure.~Treatment is usually done in an outpatient setting and typically takes about an hour to perform. As a part of the treatment, a small flexible tube (catheter) is guided into the blood vessels near the kidneys and 7 seconds of ultrasound energy is applied 2-3 times. Both sides are treated and then the catheter is removed, leaving nothing behind. After the procedure, some people go home the same day or some stay overnight.
Study: NCT05523622

Intervention type: DEVICE
Group type: OTHER
Intervention: Tono-Vera tonometer
Description: The tonometer measures intraocular pressure with a small rebound probe, similar to those used with other tonometers currently on the market, such as the iCare.

Intervention type: DEVICE
Group type: OTHER
Intervention: Goldman Applanation Tonometry
Description: This is the current gold standard for measuring eye pressure.
Study: NCT04424784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5% O2
Description: 5% oxygen will be used during oocyte retrieval, fertilization check and embryo grading
Study: NCT05989984

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ODF Iron Supplement
Description: ODF iron supplement will be admistered daily for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement in Capsules
Description: Iron supplement in capsule will be admistered daily for 8 weeks.
Study: NCT06012058

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ROTA assessment by AI
Description: The RNFL is imaged with OCT for ROTA and the data are analyzed with a deep learning model.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Optic disc assessment by AI
Description: The optic disc is imaged with color fundus camera and the data are analyzed with a deep learning model.
Study: NCT05362981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAT
Description: 2 group programs, led by trained speakers, addressing specific ED topics through written, verbal and/or behavioral exercises,

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAT
Description: 2 group programs, led by trained speakers, addressing specific ED topics through written, verbal and/or behavioral exercises,
Study: NCT05873725

Intervention type: DRUG
Intervention: Follitropin delta
Description: Evaluation of the IVF cycle using the prescribed medication

Intervention type: DRUG
Intervention: Follitropin delta
Description: Evaluation of the IVF cycle using the prescribed medication
Study: NCT05751512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG003
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab injection
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate Injection
Description: Administered intravenously
Study: NCT06296095

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell therapy
Description: Subjects were placed sequentially into three different dose groups, 5.0×107 cells/time (low-dose group), 1.5×108 cells/time (medium-dose group), and 5.0×108 cells/time (high-dose group) for dose escalation
Study: NCT06362980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-1178
Description: 200 or 300 mg, oral, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: 80mg, oral, QD
Study: NCT04749589

Intervention type: DIAGNOSTIC_TEST
Intervention: iron deficiency
Description: Its not an intervention. Its an observational study. The groups are defined based on their iron status

Intervention type: DIAGNOSTIC_TEST
Intervention: iron deficiency
Description: Its not an intervention. Its an observational study. The groups are defined based on their iron status
Study: NCT05672979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab Injection [Beovu]
Description: brolucizumab 6mg intravitreal injection
Study: NCT05429970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body resilience training
Description: MBRT is a meditation technique used to achieve relaxation)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Music listening was found, in multiple trials, to significantly reduce self-reported anxiety, physiologic indicators of anxiety, and/or sedation requirements

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol 20 mg PO BID (for 21 consecutive days), Propranolol 10mg PO BID (for 3 consecutive days POD 14-16)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etodolac
Description: Etodolac 400 mg PO BID (for 21 consecutive days)
Study: NCT05777148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: super high-flux hemodialysis
Description: Super high-flux hemodialysis (SHF-HD) is hemodialysis using Super high-flux dialyzer for 24 week then crossover to post dilution online HDF (wash out period 4 weeks)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: postdilution online hemodiafiltration
Description: hemodialysis by post dilution online HDF technique for 24 week then crossover to super high-flux HD (wash out period 4 weeks)
Study: NCT06492694

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil + wild orange essential oil supplement
Description: This supplement contains fish oil and wild orange essential oil as its active ingredients.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil supplement
Description: This supplement contains fish oil as its active ingredient.
Study: NCT05635578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sleep
Description: reiki
Study: NCT04984291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alliance Glenoid
Description: Alliance Glenoid used in Primary or Revision Total Shoulder Arthroplasty

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Identity Stem
Description: Identity Shoulder System is intended to be used in anatomic total shoulder arthroplasty, shoulder hemi-arthroplasty, or total reverse shoulder arthroplasty in both Primary or Revision Total Shoulder Arthroplasty
Study: NCT05605964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: Leuprolide acetate injection
Study: NCT05490121

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Violence, Evidence, Guidance, Action Project (VEGA) Education Intervention
Description: VEGA is a novel education intervention that has the potential to improve the preparation of healthcare and social service providers (HHSPs) to be able to effectively recognize and respond to intimate partner violence (IPV) and related forms of family violence, including child maltreatment (CM), in their clinical encounters. VEGA was developed based on systematic reviews and consultation with individuals belonging to 22 national healthcare and social service organizations, including the Royal College of Physicians and Surgeons of Canada. VEGA follows a competency-based framework and a participatory, encounter-based curriculum that includes four learning modules: (a) the epidemiology of IPV and CM; (b) strategies for safely recognizing and responding to (i) IPV and (ii) CM; and (c) principles for ensuring safe clinical encounters for IPV and CM discussions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Violence, Evidence, Guidance, Action Project (VEGA) Education Intervention
Description: VEGA is a novel education intervention that has the potential to improve the preparation of healthcare and social service providers (HHSPs) to be able to effectively recognize and respond to intimate partner violence (IPV) and related forms of family violence, including child maltreatment (CM), in their clinical encounters. VEGA was developed based on systematic reviews and consultation with individuals belonging to 22 national healthcare and social service organizations, including the Royal College of Physicians and Surgeons of Canada. VEGA follows a competency-based framework and a participatory, encounter-based curriculum that includes four learning modules: (a) the epidemiology of IPV and CM; (b) strategies for safely recognizing and responding to (i) IPV and (ii) CM; and (c) principles for ensuring safe clinical encounters for IPV and CM discussions.
Study: NCT06572228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dupilumab
Description: Administered by subcutaneous (SC) injection
Study: NCT05959382

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Loupe
Description: Magnification aid

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Loupe
Description: Magnification aid

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Operation Microscope
Description: Magnification aid
Study: NCT05756361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Based Treatment for T1D
Description: Our FBT curriculum, which has been delivered successfully in the specialty and primary care settings, has 3 components: 1. Meal planning including quality of carbohydrates and glycemic index for both parents and children while ensuring that youth have a balanced meal plan with adequate amounts of carbohydrates for optimal growth. Our FBT has a focus on Food Literacy including healthy food selection and sourcing of affordable healthy food, food preparation and preplanning, social engagement tailoring the meal plan to the needs to the family in socio cultural appropriate way and also feasibility based on logistics and economic aspects; 2. Physical activity (PA) component with shaping strategy to allow for a progressive shaping of easy PA starting, if needed, with as little as with 10 minutes of walking/day and strategies to incorporate PA in daily routines, family, and social activities; 3. Extensive behavioral component which has been shown to be very powerful in obesity treatment
Study: NCT04870814

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tactical tourniquet set up
Description: The tactical tourniquet will be set up to the upper limb and the lower limb during a maximum of 2 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tactical tourniquet set up
Description: The tactical tourniquet will be set up to the upper limb and the lower limb during a maximum of 2 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tactical tourniquet set up
Description: The tactical tourniquet will be set up to the upper limb and the lower limb during a maximum of 2 minutes.
Study: NCT06572228

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICS/LABA
Description: Administered at a blinded dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ICS/LABA
Description: Administered at a blinded dose
Study: NCT04911751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBL697
Description: 1 capsule BID of KBL697 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBL697
Description: 5 capsules BID of KBL697 or Placebo
Study: NCT05195073

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopy
Description: 3 D laparoscopy

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopy
Description: 3 D laparoscopy
Study: NCT05375474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation therapy
Description: Vitamin-K antagonists (warfarin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single antiplatelet therapy
Description: Aspirin
Study: NCT04870814

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tactical tourniquet set up
Description: The tactical tourniquet will be set up to the upper limb and the lower limb during a maximum of 2 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Medical ultrasound
Description: The efficacy of tactical tourniquet set up will be assessed by medical ultrasound.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Medical ultrasound
Description: The efficacy of tactical tourniquet set up will be assessed by medical ultrasound.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Medical ultrasound
Description: The efficacy of tactical tourniquet set up will be assessed by medical ultrasound.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Medical ultrasound
Description: The efficacy of tactical tourniquet set up will be assessed by medical ultrasound.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: The participants will have to fill a questionnaire assessing pain (for the receiver), ease of use, stability and rusticity (for the fitter).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: The participants will have to fill a questionnaire assessing pain (for the receiver), ease of use, stability and rusticity (for the fitter).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: The participants will have to fill a questionnaire assessing pain (for the receiver), ease of use, stability and rusticity (for the fitter).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: The participants will have to fill a questionnaire assessing pain (for the receiver), ease of use, stability and rusticity (for the fitter).
Study: NCT05017883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAA05 cell injection
Description: Chimeric antigen receptor T cells (car-t)~Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner,which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
Study: NCT05695248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAR-0215
Description: STAR-0215 will be administered as a subcutaneous bolus injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAR-0215
Description: STAR-0215 will be administered as a subcutaneous bolus injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAR-0215
Description: STAR-0215 will be administered as a subcutaneous bolus injection.
Study: NCT04867395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HELPix Care Plan
Description: A web application tool for CMC - Health literacy-informed, disease and medication-specific, standardized discharge instructions that will: 1) facilitate plain language provider/parent communication at hospital discharge and 2) act as stand-alone handouts that parents can use at home.
Study: NCT06384144

Intervention type: OTHER
Intervention: Expectant Management of First Trimester Miscarriage
Description: Expectant Management: Conservative management if miscarriage with follow-up booked in 2 weeks to determine whether complete miscarriage has occurred.

Intervention type: OTHER
Intervention: Medical Management of First Trimester Miscarriage
Description: Medical Management: Misoprostol taken to manage first trimester miscarriage, with follow-up booked in 2 weeks to determine whether complete miscarriage has occurred.
Study: NCT05361148

Intervention type: OTHER
Intervention: no interventions will be used
Description: This is a cohort study with no interventions.
Study: NCT04922255

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reusable Underwear
Description: Reusable Underwear are similarly available for purchase online and are absorbent underwear for bladder leak protection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Disposable urethral support
Description: The disposable urethral support is a tampon-like device that is available over the counter to help women with urinary incontinence (UI)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor physical therapy
Description: Experienced pelvic health physical therapists (at University of Pittsburgh) will complete two visits one week apart.
Study: NCT05756803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity acoustic shockwave therapy
Description: The study is being done to find out if low-intensity shockwave therapy can improve penile blood flow and restore sexual function in men with impaired erectile function.
Study: NCT05330364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 30mg/d p.o. begin at day 1, twice per week, during a 28-days cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Cladribine 5mg/m2/d i.v. d1-5, once per day, during a 28-days cycle.
Study: NCT05361148

Intervention type: OTHER
Intervention: no interventions will be used
Description: This is a cohort study with no interventions.

Intervention type: OTHER
Intervention: no interventions will be used
Description: This is a cohort study with no interventions.

Intervention type: OTHER
Intervention: no interventions will be used
Description: This is a cohort study with no interventions.

Intervention type: OTHER
Intervention: no interventions will be used
Description: This is a cohort study with no interventions.

Intervention type: OTHER
Intervention: no interventions will be used
Description: This is a cohort study with no interventions.
Study: NCT06231758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200mg
Description: Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis (eg, osteoarthritis, rheumatoid arthritis, or juvenile rheumatoid arthritis), such as inflammation, swelling, stiffness, and joint pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200mg
Description: Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis (eg, osteoarthritis, rheumatoid arthritis, or juvenile rheumatoid arthritis), such as inflammation, swelling, stiffness, and joint pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin (MET), a traditional antdiabetic drug, exerts glucose-lowering effect by activating AMPK since it is a critical enzyme in lipid and glucose metabolism
Study: NCT05638503

Intervention type: OTHER
Intervention: Left ventricular hypertrophy
Description: Hypertension with normal left ventricular geometry and left ventricular concentric remodeling

Intervention type: OTHER
Intervention: Left ventricular non-hypertrophy
Description: Hypertension with left ventricular concentric hypertrophy and left ventricular eccentric hypertrophy
Study: NCT05594836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant Calming Training
Description: Perception of Maternal Role, Maternal Attachment and Breastfeeding Self-Efficacy during Infant Calming Training
Study: NCT05276570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-RAGE
Description: single or multiple doses of ARO-RAGE by inhalation of nebulized solution
Study: NCT05460442

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caudal Block group
Description: Patients will be placed in the lateral decubitus position. After local sterilization with povidone-iodine, the sacral hiatus will be visualized at the level of the sacral Cornus by ultrasound. The needle will be advanced toward the upper third of the sacrococcygeal ligament. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament. At this level, after confirming the absence of blood or cerebrospinal fluid on aspiration, bupivacaine 0.25% (0.5 mL/kg) will be injected over 1 minute

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block
Description: Patients will receive ultrasound-guided Pericapsular nerve group block in the supine position after proper sterilization of the groin region. The needle will be inserted in-plane with the transducer. The Pericapsular nerve group block group will receive 0.5 mL/kg of (0.25%) bupivacaine after a negative aspiration